From: Temozolomide promotes genomic and phenotypic changes in glioblastoma cells
Cell line | Morphology | Proliferation/viability | Cell cycle distribution | Migration/invasion | Growth in vivo/soft agar | Concentration/treatment period | Refs |
---|---|---|---|---|---|---|---|
A172 | No change |  |  |  |  | 100 μM/1 mo | [62] |
C6 | No change | ↓ |  | ↓ | ↓ in soft agar | 100 μM/1 mo in vitro or 50 mg/kg/10 injections in vivo | this study |
D54 | Changed | ↓ | ↑ G0/G1 ↓ G2/M | ↑ |  | up to 0.5 mM/ 5 or 10 mo | [14] |
CSC |  | ↓ |  |  | ↓ in vivo |  | [10] |
HEK293 derivatives | No change | ↓ |  |  | ↓ in soft agar | up to 120 μM/ 3 mo | [23] |
HeLa derivatives | No change | No change or ↑ |  |  | ↑ in soft agar | up to 120 μM/ 3 mo | [23] |
Hs683 |  | ↓ |  | ↓ | ↓ in vivo | up to 1 mM/ 10 mo | [8] |
LN-308, LNT-229, LN-18 | No change | ↓ | No change |  |  | up to EC50/6 mo | [7] |
T98G |  | ↓ |  | No change | No change in vivo | up to 1 mM | [19] |
T98G | No change | No change |  | No change | ↑ in soft agar | 100 μM/1 mo | this study |
U87 | Changed |  |  | ↑ |  | up to IC50 = 150 µM/3 weeks | [18] |
U251 |  |  | ↑ G2/M |  |  |  | [21] |
U251 | No change | ↓ or ↑ |  | ↓ or ↑ | No change in soft agar | up to 100 μM/ 5 or 10 weeks | this study |
U373 |  | ↑ |  | ↑ | ↑ in vivo | up to 1 mM | [19] |